After attempting to get through the initial public offering window without success during 2021-2022, Elicio Therapeutics is taking its lymph node-directed cancer vaccine technology public through a reverse merger with troubled Angion Biomedica Corp., which began considering strategic options last summer after multiple clinical development setbacks with its renal disease candidate ANG-3777.
[Sidebar#SC145564]








